The stock of Sun Pharma is likely to witness buying interest as the company got permission from the US Federal Drug Administration for its Ultram ER tablets, a pain relieving drug. According to a notice issued to the BSE, the company has said that its subsidiary got an approval from the US authority for its abbreviated new drug application to market a generic version of Ultram ER, Tramadol hydrochloride extended release tablets. According to the company, Tramadol HCL ER tablets have annual sales of nearly $125 million in the US. Shares of Sun Pharma on Friday closed at Rs 512.40 on the BSE, down 1.19 per cent from its previous day close.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.